For ADAM10 and ADAM17, pharmacological inhibitors have been developed and preclinical data showed promising results in different types of cancer [149], but in terms of clinical research, there seems to be only two clinical trials using the same ADAM10/17 inhibitor (INCB7839), one completed and the other one still ongoing (NCT02141451, NCT04295759). This evidence concerns the gene ADAM10 and cancer.